Editing Larazotide acetate

== Studies on larazotide acetate ==

* ''The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study'' https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2036.2007.03413.x 
** This 2007 paper for a small pilot study noted that larazotide improved intestinal permeability.  "Following acute gluten exposure, a 70% increase in intestinal permeability was detected in the placebo group, while none was seen in the AT-1001 group."
* ''Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study'' https://doi.org/10.1111/apt.12147
** This 2012 paper noted that the study used the lactulose-to-mannitol (LAMA) ratio to measure intestinal permeability.  "No significant differences in LAMA ratios were observed between larazotide acetate and placebo groups."
* ''A Randomized, Double-Blind Study of Larazotide Acetate to Prevent the Activation of Celiac Disease During Gluten Challenge'' https://dx.doi.org/10.1038%2Fajg.2012.211 
** This 2012 paper noted: "The increase in LAMA ratio associated with the gluten challenge was not statistically significantly greater than the increase in the gluten-free control."
* ''Larazotide Acetate for Persistent Symptoms of Celiac Disease Despite a Gluten-Free Diet: A Randomized Controlled Trial'' https://dx.doi.org/10.1053%2Fj.gastro.2015.02.008
** This 2015 paper noted that "results were mixed".

MIS-C related studies:

* ''Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier'' https://doi.org/10.1172/JCI149633
** This 2021 paper argues: "These mechanistic data on MIS-C pathogenesis provide insight into targets for diagnosing, treating, and preventing MIS-C, which are urgently needed for this increasingly common severe COVID-19–related disease in children."